Oncology Biosimilars Market is expected to reach US$ 30.83 Billion by 2033 | Major Companies - Amgen Inc., Pfizer Inc., Biocon Biologics Limited, Sandoz Inc.

Market Size and Growth:

The Global Oncology Biosimilars Market size reached US$ 6.76 Billion in 2024 from US$ 5.77 Billion in 2023 and is expected to reach US$ 30.83 Billion by 2033, growing at a CAGR of 18.6% during the forecast period 2025-2033.

The Oncology Biosimilars Market refers to the development, manufacturing, and commercialization of cost-effective biologic drugs that are highly similar to approved reference oncology biologics. These products offer comparable safety, efficacy, and quality, improving patient access to cancer therapies while reducing treatment costs and supporting sustainable healthcare systems worldwide.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/oncology-biosimilars-market?sz

Recent Key Developments of United States:

✅ January 2026: Milestone regulatory nods and competitive launches redefined market dynamics, with biosimilars capturing larger shares in rituximab and trastuzumab segments due to proven savings and clinical data. Payers reported billions in projected efficiencies by mid-2026.

✅ December 2025: PBMs introduced evolved reimbursement models favoring oncology biosimilars, leading to significant price drops and expanded patient access in major U.S. health systems. This shift addressed high cancer treatment costs exceeding $70 billion annually.

✅ November 2025: The FDA issued approvals for multiple new oncology biosimilars, including versions targeting breast and lung cancers, accelerating market entry amid rising demand for cost-effective therapies. These approvals built on 2024's record highs, enabling hospitals to adopt options with 30-80% discounts over originators.

Recent Key Developments of Japan:

✅ January 2026: Celltrion's Herzuma trastuzumab biosimilar hit 74% market share, reflecting surging demand and expedited approvals for oncology therapies in key cancer types. Collaborations further diversified options for cost-effective treatments.

✅ December 2025: Government incentives boosted reimbursement for oncology monoclonal antibody biosimilars, targeting lymphoma and colorectal indications to curb rising healthcare expenses. This aligned with national efforts for affordable cancer care.

✅ November 2025: Oncology biosimilars for breast and gastric cancers, like trastuzumab equivalents, strengthened market penetration through local-global partnerships, enhancing hospital adoption amid aging demographics. Regulatory streamlining supported faster availability.

List of the Key Players in the Oncology Biosimilars Market:

Celltrion USA, Inc.
Amgen Inc.
Pfizer Inc.
Biocon Biologics Limited
Teva Pharmaceuticals USA, Inc.
Organon group of companies
Accord BioPharma
Sandoz Inc.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/oncology-biosimilars-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the Oncology Biosimilars Market:

By Product Type: Monoclonal Antibodies (mAbs), Recombinant Proteins, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoiesis-Stimulating Agents, Others.

By Indication: Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others.

By Route of Administration: Oral, Injectable.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=oncology-biosimilars-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Oncology Biosimilars market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Oncology Biosimilars Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Oncology Biosimilars market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Oncology Biosimilars Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Oncology Biosimilars Market in 2025?
◆ What is the projected growth rate of the Oncology Biosimilars Market through 2033?
◆ Who are the key players in the Oncology Biosimilars Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.